


FSCAN
Rapid and Accurate
Diagnostic Solutions

A New 3 Minute Prostate Cancer Test



- A Novel Diagnostic Method Using Light Fingerprinting -



Several diseases have recently been associated with the elevation or depletion of simple bioactive species. One species (analyte) of key importance is citrate. It is under increasing focus having been recently identified as an excellent marker for prostate cancer. Prostate Cancer (PCA) is the second leading cause of male cancer related deaths, annually taking 254,000 lives worldwide.

The current clinical screening tool for the disease is the Prostate Specific Antigen (PSA) blood test which is highly regarded as inaccurate, providing an alarming 33% false negatives and 18% false positives.



To meet the urgent need, we have set out to find a new, simple, non-invasive and accurate way to detect prostate cancer using citrate level analysis in Semen or Prostatic (PR) Fluid samples.



Our sensor is based on a rare-earth metal, Europium (Eu), which glows with a red light fingerprint that may exclusively report on the citrate concentration in the bio-fluid of interest.

The sensor compound has been specifically designed and engineered to exhibit excellent citrate sensitivity leading to the development of a simple test kit for prostate cancer detection.

This innovative assay not only benefits from high accuracy and sensitivity but also possesses a very short 3 minute test time, long shelf-life and requires a very small sample.



Our diagnostic test has been validated with excellent correspondence with a commercially available enzyme based test which not only requires 100x more sample and extensive pre-treatment, but is also much more time consuming.

In conjunction with our assay development, we have also developed a bespoke, versatile, small bench-print prototype instrumentation with its accompanying software to help us establish a quick and accurate clinical diagnosis.

This well defined test kit is now part of two clinical trial studies, which should promote this rapid, accurate, non-invasive prostate cancer test to be available to the general public via GP practices.



On a final note we are committed to provide a simple and highly accurate test kit for Prostate Cancer detection. As this novel test is only one aspect of our research we also continue to devise innovative methods and techniques that will feature in the growth of the 21st century diagnostic industry, such as our test kits in final development for Cervical Cancer, MS and Gout.....

- For more detailed information please visit www.fscanltd.com -